Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NCNA Stock Summary
In the News
Why Is NuCana (NCNA) Stock Up 102% Today?
NuCana (NASDAQ: NCNA ) stock is rising on Wednesday as the clinical-stage biopharmaceutical company's shares experience heavy trading this morning. That has more than 9.6 million shares of the company's stock changing hands as of this writing.
NuCana: Potential Turnaround In 2024 But Risky
NCNA is a beaten-down stock for numerous reasons, including failure of its prior lead candidate (Acelarin) in two phase 3 trials, as well as a limited cash runway. However, there are good reasons to believe that NCNA's current lead candidate, NUC-3373, will be successful. NUC-3373 aims to replace 5-fluorouracil (5FU) by overcoming its numerous limitations. Notably, 5FU is still used in a variety of malignancies. Importantly, 5FU-based chemotherapy regimens remain the cornerstone for treatment of colorectal cancer.
NuCana to Present at the Jefferies London Healthcare Conference
EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference.
Why Is NuCana (NCNA) Stock Down Today?
NuCana (NASDAQ: NCNA ) stock is sliding lower on Tuesday as the clinical-stage biopharmaceutical company prepares for a presentation this week. NuCana is set to attend the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 in Boston, Mass.
Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now
NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NuCana to Present at the Jefferies Healthcare Conference
EDINBURGH, United Kingdom, June 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Healthcare Conference.
Why Is NuCana (NCNA) Stock Down 36% Today?
NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company's European Patent 2955190 isn't valid.
NuCana to Participate in Two Upcoming Investor Conferences
EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming investor conferences.
NuCana: Pipeline And Major Gilead Litigation Progressing Nicely
NuCana's market cap is not reflecting the potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. The UK and EU proceedings against Gilead for alleged years-long infringement of an EU patent have important hearing dates lined up in January and March 2023.
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NCNA Financial details
NCNA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.67 | -0.81 | -0.79 | -0.62 | 0 | |
Operating cash flow per share | -0.75 | -0.57 | -0.46 | -0.45 | 0 | |
Free cash flow per share | -0.79 | -0.61 | -0.48 | -0.46 | 0 | |
Cash per share | 1.63 | 2.31 | 1.17 | 0.81 | 0 | |
Book value per share | 2 | 2.62 | 1.27 | 0.74 | 0 | |
Tangible book value per share | 1.87 | 2.49 | 1.23 | 0.7 | 0 | |
Share holders equity per share | 2 | 2.62 | 1.27 | 0.74 | 0 | |
Interest debt per share | 0.03 | 0.02 | 0.01 | -0.18 | 0 | |
Market cap | 146.37M | 124.45M | 90.88M | 28.32M | 0 | |
Enterprise value | 95.21M | 37.74M | 30.98M | -12.95M | -16.83M | |
P/E ratio | -6.84 | -4.06 | -2.24 | -0.88 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -6.14 | -5.76 | -3.81 | -1.22 | 0 | |
PFCF ratio | -5.83 | -5.35 | -3.65 | -1.2 | 0 | |
P/B Ratio | 2.3 | 1.25 | 1.39 | 0.74 | 0 | |
PTB ratio | 2.3 | 1.25 | 1.39 | 0.74 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.98 | -1.32 | -0.74 | 0.27 | 0 | |
EV to operating cash flow | -4 | -1.75 | -1.3 | 0.56 | 0.64 | |
EV to free cash flow | -3.79 | -1.62 | -1.24 | 0.55 | 0.63 | |
Earnings yield | -0.15 | -0.25 | -0.45 | -1.13 | 0 | |
Free cash flow yield | -0.17 | -0.19 | -0.27 | -0.84 | 0 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | |
Debt to assets | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
Net debt to EBITDA | 2.14 | 3.03 | 1.43 | 0.87 | 0 | |
Current ratio | 10.54 | 12.49 | 6.11 | 2.84 | 1.97 | |
Interest coverage | 0 | 0 | 0 | 3.97 | 0 | |
Income quality | 1.11 | 0.7 | 0.59 | 0.72 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.06 | 0.04 | 0.03 | 0.04 | 0.08 | |
Capex to operating cash flow | 0.05 | 0.08 | 0.04 | 0.02 | 0.02 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.76 | -1.83 | -1.13 | -0.71 | -0.83 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.5 | 6.91 | 4.74 | 3.22 | 0 | |
ROIC | -0.34 | -0.31 | -0.61 | -0.82 | 0 | |
Return on tangible assets | -0.32 | -0.3 | -0.54 | -0.57 | 0 | |
Graham Net | 1.73 | 2.37 | 1.1 | 0.58 | 0 | |
Working capital | 58.97M | 93.66M | 59.9M | 35.61M | 12.34M | |
Tangible asset value | 59.56M | 94.48M | 63.14M | 36.14M | 12.76M | |
Net current asset value | 58.41M | 93.24M | 59.69M | 35.17M | 12.1M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | |
Average receivables | 9.9M | 13.82M | 12.9M | 10.84M | 8.07M | |
Average payables | 2.43M | 2.33M | 2.04M | 3.32M | 4.09M | |
Average inventory | -906.6K | -13.82K | -12.9K | -5.67K | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.34 | -0.31 | -0.62 | -0.83 | 0 | |
Capex per share | -0.04 | -0.04 | -0.02 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.29 | -0.15 | -0.1 | -0.13 | 0 | |
Operating cash flow per share | -0.13 | -0.2 | -0.11 | -0.19 | 0 | |
Free cash flow per share | -0.13 | -0.2 | -0.11 | -0.19 | 0 | |
Cash per share | 0.81 | 0.59 | 0.47 | 0.34 | 0 | |
Book value per share | 0.74 | 0.61 | 0.52 | 0.41 | 0 | |
Tangible book value per share | 0.7 | 0.56 | 0.47 | 0.41 | 0 | |
Share holders equity per share | 0.74 | 0.61 | 0.52 | 0.41 | 0 | |
Interest debt per share | 0.1 | 0.03 | 0.01 | 0.01 | 0 | |
Market cap | 28.35M | 50.28M | 32.81M | 26.58M | 0 | |
Enterprise value | -12.93M | 19.88M | 8.73M | 9.23M | -16.83M | |
P/E ratio | -0.47 | -1.6 | -1.52 | -0.99 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -4.18 | -4.87 | -5.61 | -2.61 | 0 | |
PFCF ratio | -4.11 | -4.79 | -5.48 | -2.59 | 0 | |
P/B Ratio | 0.74 | 1.58 | 1.2 | 1.22 | 0 | |
PTB ratio | 0.74 | 1.58 | 1.2 | 1.22 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 1.06 | -2.61 | -1.74 | -1 | 2.39 | |
EV to operating cash flow | 1.91 | -1.92 | -1.49 | -0.91 | 218.56 | |
EV to free cash flow | 1.87 | -1.89 | -1.46 | -0.9 | 96.72 | |
Earnings yield | -0.54 | -0.16 | -0.17 | -0.25 | 0 | |
Free cash flow yield | -0.24 | -0.21 | -0.18 | -0.39 | 0 | |
Debt to equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 3.38 | 3.99 | 4.81 | 1.88 | 2.39 | |
Current ratio | 2.84 | 2.73 | 2.8 | 2.57 | 1.97 | |
Interest coverage | -3.67 | -8.29 | 0 | 0 | 0 | |
Income quality | 0.45 | 1.31 | 1.08 | 1.52 | 0.01 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.04 | 0.05 | 0.06 | 0.08 | 0.08 | |
Capex to operating cash flow | 0.02 | 0.02 | 0.02 | 0.01 | 1.26 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.96 | -1.11 | -0.94 | -0.58 | -0.69 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 2.22 | 1.43 | 1.1 | 1.09 | 0 | |
ROIC | -0.39 | -0.25 | -0.2 | -0.3 | -0.5 | |
Return on tangible assets | -0.27 | -0.17 | -0.14 | -0.21 | -0.3 | |
Graham Net | 0.58 | 0.44 | 0.36 | 0.29 | 0 | |
Working capital | 35.61M | 28.78M | 24.35M | 18.73M | 12.34M | |
Tangible asset value | 36.14M | 29.28M | 24.83M | 19.19M | 12.76M | |
Net current asset value | 35.17M | 28.38M | 24.02M | 18.45M | 12.1M | |
Invested capital | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | |
Average receivables | 11M | 11.02M | 11.19M | 11.75M | 9.33M | |
Average payables | 5.21M | 5.25M | 5.19M | 4.93M | 4.27M | |
Average inventory | -3.53M | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.39 | -0.25 | -0.2 | -0.31 | -0.51 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NCNA Frequently Asked Questions
What is NuCana plc stock symbol ?
NuCana plc is a GB stock and trading under the symbol NCNA
What is NuCana plc stock quote today ?
NuCana plc stock price is $0.26 today.
Is NuCana plc stock public?
Yes, NuCana plc is a publicly traded company.